RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
27 10 2023
Historique:
accepted: 24 08 2023
revised: 10 08 2023
received: 09 05 2023
medline: 30 10 2023
pubmed: 12 9 2023
entrez: 12 9 2023
Statut: ppublish

Résumé

Breast cancer linked with BRCA1/2 mutations commonly recur and resist current therapies, including PARP inhibitors. Given the lack of effective targeted therapies for BRCA1-mutant cancers, we sought to identify novel targets to selectively kill these cancers. Here, we report that loss of RNF8 significantly protects Brca1-mutant mice against mammary tumorigenesis. RNF8 deficiency in human BRCA1-mutant breast cancer cells was found to promote R-loop accumulation and replication fork instability, leading to increased DNA damage, senescence, and synthetic lethality. Mechanistically, RNF8 interacts with XRN2, which is crucial for transcription termination and R-loop resolution. We report that RNF8 ubiquitylates XRN2 to facilitate its recruitment to R-loop-prone genomic loci and that RNF8 deficiency in BRCA1-mutant breast cancer cells decreases XRN2 occupancy at R-loop-prone sites, thereby promoting R-loop accumulation, transcription-replication collisions, excessive genomic instability, and cancer cell death. Collectively, our work identifies a synthetic lethal interaction between RNF8 and BRCA1, which is mediated by a pathological accumulation of R-loops.

Identifiants

pubmed: 37697435
pii: 7269184
doi: 10.1093/nar/gkad733
pmc: PMC10602868
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
DNA-Binding Proteins 0
Exoribonucleases EC 3.1.-
RNF8 protein, human 0
Ubiquitin-Protein Ligases EC 2.3.2.27
XRN2 protein, human EC 3.1.13.1
Brca1 protein, mouse 0
Rnf8 protein, mouse EC 2.3.2.27
Xrn2 protein, mouse EC 3.1.11.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10484-10505

Subventions

Organisme : Cancer Research UK
ID : C17183/A23303
Pays : United Kingdom

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
J Clin Invest. 2018 Oct 1;128(10):4525-4542
pubmed: 30222135
Genes Dev. 2004 May 15;18(10):1144-53
pubmed: 15131084
Nature. 2015 Nov 19;527(7578):389-93
pubmed: 26503038
Cancer Metastasis Rev. 2013 Jun;32(1-2):25-37
pubmed: 23093327
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Cell. 2017 Aug 10;170(4):787-799.e18
pubmed: 28802046
Trends Genet. 2021 Jun;37(6):566-581
pubmed: 33485674
Cell. 2009 Feb 6;136(3):435-46
pubmed: 19203579
Cell Rep. 2019 Nov 26;29(9):2890-2900.e5
pubmed: 31775053
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2020 Sep;585(7824):298-302
pubmed: 32669707
PLoS Genet. 2008 Jun 27;4(6):e1000110
pubmed: 18584027
J Exp Med. 2010 May 10;207(5):983-97
pubmed: 20385750
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Methods Enzymol. 2017;591:55-82
pubmed: 28645379
Cell. 2010 Jun 11;141(6):970-81
pubmed: 20550933
Cell Rep. 2018 May 8;23(6):1891-1905
pubmed: 29742442
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Cancer Res. 2020 Nov 1;80(21):4601-4609
pubmed: 32747362
Genes Dev. 2014 Jul 1;28(13):1384-96
pubmed: 24990962
Cell. 2019 Oct 17;179(3):604-618
pubmed: 31607512
Mol Cell. 2011 Jun 24;42(6):794-805
pubmed: 21700224
Mol Cell. 2017 May 18;66(4):458-472.e5
pubmed: 28525740
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Life Sci Alliance. 2020 Aug 3;3(10):
pubmed: 32747416
J Cell Biol. 2021 Sep 6;220(9):
pubmed: 34232287
Nat Rev Cancer. 2015 May;15(5):276-89
pubmed: 25907220
Nat Rev Clin Oncol. 2018 Sep;15(9):564-576
pubmed: 29955114
PLoS Genet. 2016 Jul 20;12(7):e1006107
pubmed: 27437695
Mol Cell. 2012 May 11;46(3):311-24
pubmed: 22483619
Nature. 2023 Jan;613(7942):187-194
pubmed: 36544021
Mol Cell. 2015 Feb 19;57(4):636-647
pubmed: 25699710
Nucleic Acids Res. 2018 Nov 16;46(20):11002-11013
pubmed: 30169671
Annu Rev Cancer Biol. 2018 Mar;2:313-336
pubmed: 30345412
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cancer Cell. 2012 Jul 10;22(1):106-16
pubmed: 22789542
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
DNA Repair (Amst). 2018 Nov;71:69-81
pubmed: 30190235
Genes Dev. 2011 Oct 1;25(19):2041-56
pubmed: 21979917
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33529165
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cancer Res. 2006 Jan 1;66(1):41-5
pubmed: 16397213
Neoplasia. 2009 Jul;11(7):683-91
pubmed: 19568413
Nat Commun. 2020 Aug 7;11(1):3940
pubmed: 32769985
Oncogene. 2021 Apr;40(17):3001-3014
pubmed: 33716297
Genes Dev. 2014 Sep 1;28(17):1957-75
pubmed: 25184681
Mol Cell. 2022 Jun 16;82(12):2267-2297
pubmed: 35508167
Nat Rev Mol Cell Biol. 2014 Jan;15(1):7-18
pubmed: 24326623
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Rev Mol Cell Biol. 2020 May;21(5):284-299
pubmed: 32094664
Nat Struct Mol Biol. 2010 Jun;17(6):688-95
pubmed: 20453858
Nucleic Acids Res. 2023 Apr 11;51(6):2818-2837
pubmed: 36864660
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Cell. 2017 Aug 10;170(4):774-786.e19
pubmed: 28802045
Nat Rev Mol Cell Biol. 2016 May 23;17(6):379-94
pubmed: 27211488
Genome Res. 2018 Sep;28(9):1405-1414
pubmed: 30108179
Nucleic Acids Res. 2020 Jun 19;48(11):6032-6052
pubmed: 32427332
Mol Cell. 2017 Oct 19;68(2):414-430.e8
pubmed: 29053959
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325

Auteurs

Rehna Krishnan (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Mariah Lapierre (M)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Brandon Gautreau (B)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Kevin C J Nixon (KCJ)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Samah El Ghamrasni (S)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Parasvi S Patel (PS)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, Ontario M5G 1L7, Canada.

Jun Hao (J)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

V Talya Yerlici (VT)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Kiran Kumar Naidu Guturi (KKN)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Jonathan St-Germain (J)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Francesca Mateo (F)

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.

Amine Saad (A)

Segal Cancer Centre and Lady Davis Institute for Medical Research, Departments of Medicine and Oncology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Arash Algouneh (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Rebecca Earnshaw (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Duan Shili (D)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Alma Seitova (A)

Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada.

Joshua Miller (J)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Negin Khosraviani (N)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Adam Penn (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Brandon Ho (B)

Department of Biochemistry and Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.

Otto Sanchez (O)

Ontario Tech University, 2000 Simcoe Street North Oshawa, Ontario L1G 0C5, Canada.

M Prakash Hande (MP)

Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Jean-Yves Masson (JY)

Genome Stability Laboratory, CHU de Québec Research Center, Oncology Axis; Department of Molecular Biology, Medical Biochemistry and Pathology; Laval University Cancer Research Center, 9 McMahon, Québec City, Québec G1R 2J6, Canada.

Grant W Brown (GW)

Department of Biochemistry and Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.

Moulay Alaoui-Jamali (M)

Segal Cancer Centre and Lady Davis Institute for Medical Research, Departments of Medicine and Oncology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

John J Reynolds (JJ)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Cheryl Arrowsmith (C)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, Ontario M5G 1L7, Canada.
Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada.

Brian Raught (B)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, Ontario M5G 1L7, Canada.

Miguel A Pujana (MA)

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.

Karim Mekhail (K)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Grant S Stewart (GS)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Anne Hakem (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.

Razqallah Hakem (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Department of Medical Biophysics, University of Toronto, Ontario M5G 1L7, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH